Application Detail
Status
ClosedDescription of Medical Service
Testing of tumour material in patients with non-small cell lung cancer (NSCLC) to detect chromosomal rearrangements in the ROS1 gene to determine eligibility for treatment with Xalkori (crizotinib) through the PBS.PBS subsidy will also be sought for Xalkori (crizotinib) for the treatment of patients with ROS1-rearranged NSCLC.
Description of Medical Condition
Patients with non-squamous non-small cell lung cancer (NSCLC).Reason for Application
New MBS itemMedical Service Type
InvestigativeCo-dependent technology
Previous Application Number
Not ApplicableAssociated Documentation
Application Form
Application Form (PDF 314 KB)Application Form (Word 559 KB)
PICO Confirmation
PICO Confirmation (PDF 330 KB)PICO Confirmation (Word 204 KB)
Assessment Report
-Public Summary Document
Public Summary Document (PDF 320 KB)Public Summary Document (Word 120 KB)
Meetings for this Application
PASC
8 December 2016ESC
5 October 2017MSAC
23 November 201726-27 July 2018